Mankind Pharma is intensifying its focus on the specialty business by addressing key therapeutic gaps in a highly competitive market. The company is expanding its presence in chronic disease areas such as heart failure and has launched products like insulin glargine.
Launched during the pandemic, Mankind Specialties has rapidly grown over the last four years, expanding from two to nine therapeutic segments, according to Atish Majumdar, Senior President (Sales and Marketing) at Mankind Pharma.
The company’s specialty division covers areas like cardiology, diabetes, respiratory diseases, gastroenterology, neurology, oncology, and urology. Majumdar emphasized that Mankind Pharma is not a late entrant in the specialty segment, contrary to market perception, but is sharpening its focus to address the rising prevalence of chronic conditions.
As reported by thehindubusinessline.com, Mankind Pharma has leveraged local acquisitions from Panacea Biotec and Dr. Reddy’s Laboratories, while also establishing partnerships with global companies like Novartis and AstraZeneca to bolster its specialty portfolio.
